Comments by patients in the pilot test on every page of the decision aid and adaptations made by the steering group
| Main element | Comments | Adaptations made |
| I: Health condition and personal risk factors | Gout flares can occur in more body parts than the big toe, for example in the ears | Other commonly involved joints added to the text |
| Gout can give more severe problems than only flares and pain. Elaborate on other severe problems | Tophi in skin and bone explicitly mentioned | |
| Some risk factors are not applicable for individual patients | The risk factor personalised by adding tick boxes | |
| II: The personalised risk on future gout flares without ULT | Not clear that the icon arrays are gout flares in the first metatarsophalangeal joint | Specifically added that the most common gout flare location was illustrated |
| Not clear if the risk of future gout flares was independent of the personal sUA level | The DA was personalised for patients with an initial sUA level between (>0.36–<0.55 mmol/L and ≥0.55 mmol/L). | |
| III: Lifestyle changes and treatment of acute flares | Give more detailed information for advices related to proportions (eg, drinks or red meat) | Detailed for alcohol consumption |
| Specify the non-citrus fruits with examples | Overruled/rejected by the steering group | |
| IV: Effect of ULT | Mention the specific sUA target of ULT | Added the sUA target of ≤0.36 mmol/L |
| Mention number of future flares that will occur within the period considered in the figure with icon arrays | Added icon arrays presenting number of patients with at least one gout flare | |
| V: Option grid | Mention here also the generic name of ULTs. A patient that used desuric, did not know this was also called benzbromaron | Generic names were added to the option grid for all the ULTs |
| Increase font style within the option grid | Font of symbols and text was increased | |
| Add rasburicase | The DA clarifies only ULTs for long-term control of sUA are included | |
| VI: Final treatment decision | Include the day of the follow-up in the DA | Added a section were the next visit can be mentioned (eg, time and date) |
DA, decision aid; sUA, serum uric acid; ULT, urate-lowering therapy.